Get to know our clinical trials
Clinical trial evaluating the safety and efficacy of pivekimab sunirine (PVEK) in combination with venetoclax and azacitidine in adult participants with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy
THE AIM OF THIS STUDY IS TO DETERMINE THE SAFETY AND EFFICACY (HOW WELL THE STUDY DRUGS WORK) OF PVEK IN COMBINATION WITH VENETOCLAX (VEN) AND AZACITIDINE (AZA) IN ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE UNABLE TO RECEIVE INTENSIVE CHEMOTHERAPY.
Technical Summary
- PHASE 2/3, RANDOMIZED STUDY EVALUATING THE SAFETY AND EFFICACY OF PIVEKIMAB SUNIRINE (PVEK) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN ADULT PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
- Code EudraCT: 2025-523724-47
- Protocol number: M26-092
- Promoter: Abbvie Spain SLU
- Molecule/Drug: Pivekimab Sunirine en combinación con Venetoclax y Azacitidina
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.